These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35733913)

  • 41. Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21).
    Sader HS; Castanheira M; Kimbrough JH; Kantro V; Mendes RE
    JAC Antimicrob Resist; 2023 Apr; 5(2):dlad032. PubMed ID: 36968952
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ceftazidime - Avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey.
    Ozger HS; Evren E; Yildiz SS; Erol C; Bayrakdar F; Azap O; Azap A; Senol E
    Acta Microbiol Immunol Hung; 2021 Jul; ():. PubMed ID: 34324428
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against
    Han R; Yang X; Yang Y; Guo Y; Yin D; Ding L; Wu S; Zhu D; Hu F
    Microbiol Spectr; 2022 Feb; 10(1):e0109221. PubMed ID: 35019685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018.
    Kristóf K; Adámková V; Adler A; Gospodarek-Komkowska E; Rafila A; Billová S; Możejko-Pastewka B; Kiss F
    Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115420. PubMed ID: 34091111
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 48. Performance Evaluation of the Gradient Diffusion Strip Method and Disk Diffusion Method for Ceftazidime-Avibactam Against
    Zhang J; Li G; Zhang G; Kang W; Duan S; Wang T; Li J; Huangfu Z; Yang Q; Xu Y; Jia W; Sun H
    Front Microbiol; 2021; 12():710526. PubMed ID: 34603236
    [No Abstract]   [Full Text] [Related]  

  • 49. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
    Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR;
    Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).
    Nichols WW; de Jonge BL; Kazmierczak KM; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4743-9. PubMed ID: 27216074
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the
    Al-Sweih N; Jamal W; Mokaddas E; Habashy N; Kurdi A; Mohamed N
    JAC Antimicrob Resist; 2021 Dec; 3(4):dlab159. PubMed ID: 36479234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association Between Types of Carbapenemase and Clinical Outcomes of Infection Due to Carbapenem Resistance Enterobacterales.
    Pudpong K; Pattharachayakul S; Santimaleeworagun W; Nwabor OF; Laohaprertthisan V; Hortiwakul T; Charernmak B; Chusri S
    Infect Drug Resist; 2022; 15():3025-3037. PubMed ID: 35720254
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
    Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program.
    Lin LY; Debabov D; Chang W; Stone G; Riccobene T
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651
    [No Abstract]   [Full Text] [Related]  

  • 55. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15.
    Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
    J Antimicrob Chemother; 2018 Oct; 73(10):2782-2788. PubMed ID: 30010894
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19).
    Shortridge D; Carvalhaes C; Deshpande L; Castanheira M
    J Antimicrob Chemother; 2021 Sep; 76(10):2600-2605. PubMed ID: 34302173
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 58. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Screening for Metallo-Beta-Lactamases Using Non-Carbapenem Agents: Effective Detection of MBL-Producing
    Takei K; Kanamori H; Nakayama A; Chiba M; Takei Y; Seike I; Kitamura C; Baba H; Oshima K; Tokuda K
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508242
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.